Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4755734 | 1.00 | LMNA (0.44) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL1272496 | 1.00 | LMNA (0.44) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL4756817 | 1.00 | LMNA (0.44) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL50290 | 1.00 | — | — | |
| SCHEMBL231055 | 1.00 | LMNA (0.44) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL1881247 | 1.00 | LMNA (0.44) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL50313 | 1.00 | — | — | |
| SCHEMBL3595771 | 1.00 | LMNA (0.44) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL1435928 | 1.00 | LMNA (0.44) | LMNAALDH1A1TSHRHSD17B10MEN1 | |
| SCHEMBL1875895 | 1.00 | LMNA (0.44) | LMNAALDH1A1TSHRHSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1641 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4182737-B1 | OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2024-07-03 | — | — | EP | claimed |
| WO-2024089310-A1 | BIODEGRADABLE IMINOSUGARS AND AMINO CYCLITOL GLYCOSIDES INHIBITING ALPHA-GLUCOSIDASE WITH SYNERGISTIC INSECTICIDE OR ACARICIDE ACTIVITY OR BOTH | FRANCISCO ARAGÓN S.L.U (ES) | 2024-05-02 | — | — | WO | claimed |
| US-20240026078-A1 | Polymer taking the form of a pulverulent solid and having properties for thickening polar media | SOCIETE D'EXPLOITATION DE PRODUITS POUR LES INDUSTRIES CHIMIQUES SEPPIC (FR) | 2024-01-25 | — | — | US | claimed |
| CN-117222690-A | Polymer in the form of a powdery solid and having the property of thickening polar medium | 化工产品开发公司SEPPIC | 2023-12-12 | — | — | CN | claimed |
| US-20230372508-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. | 2023-11-23 | — | — | US | claimed |
| WO-2023225650-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. (US) | 2023-11-23 | — | — | WO | claimed |
| EP-4259693-A1 | POLYMER TAKING THE FORM OF A PULVERULENT SOLID AND HAVING PROPERTIES FOR THICKENING POLAR MEDIA | Société d'Exploitation de Produits pour les Industries Chimiques SEPPIC (FR) | 2023-10-18 | — | — | EP | claimed |
| EP-3889135-B1 | COMPOUNDS FOR OPTICALLY ACTIVE DEVICES | AMO Ireland (IE) | 2023-08-02 | — | — | EP | claimed |
| CN-112358687-B | Flame-retardant polypropylene composition and preparation method thereof | 江苏金发科技新材料有限公司 | 2023-06-20 | — | — | CN | claimed |
| CN-111820417-B | Dried orange peel oil microcapsule and preparation method thereof | 广州绿萃生物科技有限公司 | 2022-10-04 | — | — | CN | claimed |
| EP-0868469-A1 | WAX DEPOSIT INHIBITORS | BP EXPLORATION OPERATING COMPANY LIMITED (GB) | 1998-10-07 | — | — | EP | claimed |
| WO-1997023547-A1 | WAX DEPOSIT INHIBITORS | BP EXPLORATION OPERATING COMPANY LIMITED (GB) | 1997-07-03 | — | — | WO | claimed |
| US-5288589-A | Storage stability | E.I. DU PONT DE NEMOURS AND COMPANY | 1994-02-22 | — | — | US | claimed |
| EP-0281360-B1 | HYDROPHOBICALLY MODIFIED NON-IONIC POLYGALACTOMANNAN ETHERS | STEIN, HALL & CO., INC. (US) | 1993-09-01 | — | — | EP | claimed |
| US-5179083-A | Coating composition containing as thickeners polygalactomannans modified with hydrophilic and hydrophobic groups | STEIN, HALL & CO., INC. (US) | 1993-01-12 | — | — | US | claimed |
| US-5167950-A | Antiseptics | S. C. JOHNSON & SON | 1992-12-01 | — | — | US | claimed |
| EP-0211550-B1 | COMPOSITION FOR PERSONAL CARE PRODUCTS COMPRISING ALKOXYLATED FATTY ALCOHOL AND POLYSILOXANE | DEUTSCHE ICI GMBH (DE) | 1991-04-10 | — | — | EP | claimed |
| US-4870167-A | THICKENERS FOR AQUEOUS SYSTEMS | HI-TEK POLYMERS, INC. (US) | 1989-09-26 | — | — | US | claimed |
| EP-0281360-A1 | Hydrophobically modified non-ionic polygalactomannan ethers | STEIN, HALL & CO., INC. (US) | 1988-09-07 | — | — | EP | claimed |
| EP-0211550-A2 | Composition for personal care products comprising alkoxylated fatty alcohol and polysiloxane | DEUTSCHE ICI GMBH (DE) | 1987-02-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240026078-A1 | Polymer taking the form of a pulverulent solid and having properties for thickening polar media | PGAM1, GLUL, SGTA | LMNA 3105/4885ALDH1A1 4362/4885TSHR 3936/4885 |
| US-20230372508-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | DNPEP, LNPEP, FGB | LMNA 1349/4885ALDH1A1 1942/4885TSHR 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.